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ScienceDirectThe feline and human immunodeficiency viruses (FIV and HIV)
target helper T cells selectively, and in doing so they induce a
profound immune dysfunction. The primary determinant of HIV
cell tropism is the expression pattern of the primary viral
receptor CD4 and co-receptor(s), such as CXCR4 and CCR5.
FIV employs a distinct strategy to target helper T cells; a high
affinity interaction with CD134 (OX40) is followed by binding of
the virus to its sole co-receptor, CXCR4. Recent studies have
demonstrated that the way in which FIV interacts with its
primary receptor, CD134, alters as infection progresses,
changing the cell tropism of the virus. This review examines the
contribution of the virus–receptor interaction to replication in
vivo as well as the significance of these findings to the
development of vaccines and therapeutics.
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The genus Felis is thought to have emerged close to 6.2
million years ago, during the late Miocene epoch [1].
Genetically, domestic cats are indistinguishable from the
African wildcat, Felis sylvestris lybica, and archaeological
evidence confirms that the close relationship between cats
and humans was evident nearly 10 000 years ago in the
Middle East [2]. The Felis lineage has suffered invasions by
viruses from three subfamilies of the retroviridae; the spu-
mavirus FeFV (feline foamy virus), the gammaretrovirus
FeLV (feline leukaemia virus), and the lentivirus FIV
(feline immunodeficiency virus). Lentiviruses are endemic
Open access under CC BY license.Current Opinion in Virology 2013, 3:670–675 in Felidae species (reviewed in [3]) and appear to have
invaded species such as the American puma (P. concolor)
many thousands of years ago, prior to the spread of pumas
from South America to North America (10–12 000 years
ago, after the last ice age). In contrast, the absence of
lentiviruses from the majority of species closely related
to the domestic cat suggests a recent introduction and
spread subsequent to domestication. The relatively recent
spread of FIV through the domestic cat population and the
striking similarities between the pathogenesis of FIV in
cats, and of AIDS in HIV-infected individuals offers a
unique opportunity to compare the evolution of the
host–virus relationship and the development of immunity
to infection.
FIV targets CD4+ helper T cells via an initial high affinity
interaction between Env and CD134 (OX40) [4,5] and
a subsequent interaction with the chemokine receptor
CXCR4 [6,7]. Expression of CD134 in the cat is restricted
largely to activated CD4+ T cells [8]. Accordingly, FIV
infection of the cat results in a progressive depletion of
CD4+ helper T cells and the development of an AIDS-
like immune dysfunction. The ensuing immunodefi-
ciency manifests with chronic gingivitis and stomatitis,
anorexia, cachexia, neurological signs and an increased
incidence of malignancy.
Although the selective targeting of FIV to helper T cells
may be explained by the restricted expression pattern of
CD134, in early infection, the primary cellular targets for
the virus are not only CD4+ helper T cells, but also
monocytes. Later in infection the tropism of the virus
extends further to encompass both CD8+ T cells and B
cells (reviewed in [9]). CD134 was first described as a
surface antigen that was expressed almost exclusively on
CD4+ T cells [10], thus the extended tropism of FIV
during the course of infection would seem counter-intui-
tive. The development of antibody reagents with which
the surface expression of feline CD134 may be measured,
confirmed the expression of CD134 on feline CD4+ T
cells [5,8] and monocyte-derived macrophages [8],
with lower levels of expression on a minor population
of activated CD8+ T cells and on CD45R+ (B220) B cells
[8] (Figure 1). The up-regulation of CD134 on feline
CD4+ T cells following activation [4,5], and the high
levels of surface expression achieved [8], are consistent
with the selective targeting of these cells in early in-
fection. While CD134 expression is ostensibly undetect-
able on feline peripheral blood (CD14+) monocytes,
weak expression can be detected on splenic macrophageswww.sciencedirect.com
FIV replication Willett and Hosie 671
Figure 1
Fluorescence intensity 


















100 10 1 10 2 10 3 10 0 10 1 10 2 10 3




CD14 CD134 CD4  CD134 
Monocyte (M) gate 
A







Lymphocyte (L) gate 
Current Opinion in Virology
Restriction of feline CD134 expression to CD4+ T cells. CD134 expression was evaluated by flow cytometry on feline peripheral blood mononuclear
cells, setting analysis gates for either lymphocytes (L), monocytes (M) or neutrophils (N). While CD14 expression was restricted primarily to the
monocyte gate (upper left panel, green), CD134 expression (red) localised predominantly to the lymphocyte gate, coincident with the expression of
CD4 (upper right panel). Additional CD134 expression was evident in the neutrophil analysis gate, consistent with the reported expression of CD134 on
human neutrophils [43].in culture and is upregulated following activation with
lipopolysaccharide [8]. Although CD134 is expressed at
lower levels on macrophages than on activated CD4+
helper T cells, since macrophages are rich in CXCR4, a
scenario may be envisaged whereby following initial in-
fection and spread, the virus disseminates into compart-
ments where CD134 expression is a limiting factor,
principally cells of the monocyte/macrophage lineage,
and as yet uncharacterised subpopulations of B220+ B
cells and activated CD8+ T cells.
Not all FIVs bind CD134 in the same way
The primary determinant of the FIV Env–CD134 inter-
action has been mapped to the first cysteine-rich domain
(CRD1) of CD134 [11,12]. As human CD134 does not
mediate FIV infection [4] (one of the primary barriers
to the transmission of FIV from cats to humans), chi-
meric CD134 molecules based on human CD134 and
which bear the CRD1 of feline CD134 will support
infection with selected strains of FIV [11,12]. Indeed,
using this approach, a fully functional receptor for the
PPR strain of FIV could be reconstituted by exchanging
residues H45S, R59G, S60D, N62D, V64K in humanwww.sciencedirect.com CD134 [11]. Importantly, well-characterised patho-
genic strains of FIV, namely C-PGammer and GL8
(Glasgow-8) require additional determinants in the sec-
ond cysteine-rich domain (CRD-2) of CD134 for in-
fection [13]. C-PGammer was derived by serial
passage of plasma-borne virus during the acute phase
of infection [14] while GL8 was isolated from a cat
during a brief episode of illness during the protracted
latent period of infection (subsequently the cat lived for
a further eight years). Thus, these viruses are likely
representative of viruses that dominate in early infection
and, as such, may share properties with viruses that are
transmitted between cats in nature. Accordingly, C-
PGammer and GL8-like viruses may serve as biologi-
cally relevant challenge strains for trials of candidate
vaccines. The amino acid motif 78NYE80 at the crown
of a loop in CD134 CRD2 that participates in the
interaction between CD134 and its cognate ligand
(CD134L) is the essential determinant in CRD2 for
CD134-usage by C-PGammer and GL8 (Figure 2). That
GL8 and C-PGammer should be dependent upon
residues distal to the projected Env binding face on
CD134 is intriguing and may indicate that these virusesCurrent Opinion in Virology 2013, 3:670–675
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Residues critical to the function of feline CD134 as a receptor for FIV.
Binding and syncytium formation by CRD2-independent strains is
conferred upon human CD134 by inserting SER-45, GLY-59, ASP-60,
ASP-62 and LYS-64 from CRD1 (shown in green) into human CD134.
CRD2-dependent strains require additional determinants in CRD2, ASN-
78, TYR-79 and GLU-80 (shown in purple) for the receptor to function.
Structures were modelled by submitting feline CD134 and CD134L
sequences (AB128982 and DQ269941) to the SWISS-MODEL
automated protein modelling server [44].recognise a specific CD134 conformation that is sensi-
tive to the CD134L–CD134 interaction [15].
While the residues on CD134 that are important for FIV
Env binding have been described [11,12,13], the
corresponding receptor binding determinants on Env
are less well characterised. It is known that, with disease
progression, viral variants emerge which infect host cells
via a direct interaction with CXCR4 (CD134-indepen-
dent infection). Critical determinants of CD134-inde-
pendence reside in the V3-loop and single glutamate to
lysine mutations in residues 407 and 409 of V3 promote
CXCR4-dependent syncytium formation [16]. In vivo,
there is a strong selective pressure to restore a glutamate
residue at these positions and revert to virulence [16].
One of the driving forces for this reversion may be
escape from neutralising antibodies induced by
CD134-binding; a CD134-independent E407K mutant
of PPR was readily susceptible to CD134-dependent
neutralising antibodies [17].
Evolution of CD134 usage in vivo
The virus–receptor interaction is a major determinant of
the in vivo replicative capacity of HIV. For example, ex
vivo analyses of primary HIV-1 isolates revealed that viralCurrent Opinion in Virology 2013, 3:670–675 fitness mapped to the env gene [18,19]. Similarly, a
comparison of the envs from two primary isolates of
HIV-1 demonstrated that the reduced fitness associated
with a clade C Env was associated with weak cell surface
binding, inefficient entry, and an increased sensitivity to
CCR5 antagonists and fusion inhibitors [20]. Moreover,
HIV-1 clade B envelopes from early infection tend to
harbour amino acid signatures that favour efficient
expression of Env in infected cells, enhancing Env
incorporation into nascent virions and facilitating replica-
tion to a high titre [21,22]. These signature sequences are
lost during chronic infection under selective pressure
from the adaptive immune response [21,22]. In this con-
text, the requirement for the 78NYE80 motif within the
CRD2 of CD134 for both C-PGammer and GL8 Envs
may reflect a more efficient interaction between the
viruses and their receptors. While infection with C-
PGammer and GL8 is CRD2-dependent, strains such
as PPR and B2542 have no such requirement. We pos-
tulated that CRD2-dependent infection might represent
a feature of viruses that dominate ‘early’ in infection,
facilitating both transmission and infection. Following
establishment in the host, variants may then emerge that
have a reduced requirement for an interaction with CRD2
of CD134, and in some cases may even lose the require-
ment for CRD2-binding altogether (as in PPR and
B2542). This working hypothesis predicts that CRD2-
independent viruses will be more prevalent in the ‘late’
stage of infection. In order to test this hypothesis, the
receptor usage of viruses isolated six years post-infection
with a clonal preparation of the CRD2-dependent GL8
strain was examined [23]. While viral variants were
identified that remained near identical to the challenge
inoculum, additional variants were identified that dis-
played differences in the amino acid sequence of Env
that switched the viral phenotype to CRD2-independent.
Furthermore, these viruses displayed altered sensitivities
to antagonists of the Env–CD134 interaction. While GL8
was markedly CRD2-dependent, resistant to anti-CD134
antibody and soluble CD134L (sCD134L) and sensitive
to soluble CD134 (sCD134); variants that evolved in vivo
were highly sensitive to anti-CD134 antibody, sensitive
to sCD134L and resistant to sCD134 [23]. That ‘late’
variants of GL8 should be sensitive to inhibition by anti-
CD134 antibody is intriguing and may be significant,
given that autoantibodies against CD134 have been
detected in a proportion of FIV-infected cats [24] and
these autoantibodies were capable of blocking infection
with the CRD2-independent PPR strain of FIV [24].
Binding of the autoantibodies recognising CD134 in FIV
infected cats required pre-engagement of CD134 with
Env [24], reminiscent of the polyreactive CD4-induced
antibody 21c that recognises the HIV-1 Env–CD4 com-
plex and binds determinants on both Env and CD4 [25].
Polyclonal B cell activation is a feature of both FIV and
HIV infections and anti-CD4 autoantibodies have been
well documented in HIV infection. Whether anti-CD134www.sciencedirect.com
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response to antibodies raised against the viral Env protein
or are epiphenomena related to the generalised immune
dysregulation is unclear; nevertheless, the presence of
such antibodies in the sera of FIV-infected cats may have
the direct effect of suppressing the emergence of CRD2-
independent viruses.
Engagement of CD4+ T cell-expressed CD134 by anti-
gen presenting cell (APC)-expressed CD134L enhances
the expansion and survival of antigen-specific CD4+ T
cells (reviewed in [26]). Similarly, CD134L expressed on
CD4+ T cells may contribute to the maintenance of
CD4+ T cell longevity through T cell–T cell interactions
[27]. Accordingly, the FIV–CD134 interaction may influ-
ence profoundly the development of antigen-specific
immune responses as FIV will target preferentially the
very cells that have been triggered to expand in response
to infection, just as HIV infects HIV-specific CD4+ T
cells preferentially [28]. Whether, APC-expressed
CD134L, locally released soluble CD134 and CD134L,
or anti-CD134 autoantibodies influence viral entry and
expansion in vivo remains to be established. However, as
the CD134L–CD134 interaction is a prerequisite for the
expansion of antigen-specific CD4+ T cells, it would
seem likely that the virus would have evolved to associate
with the ligand bound form of CD134. Support for this
model comes from structural studies indicating that the
primary binding face for Env on CD134 is distinct from
the CD134L-binding face mapped by X-ray crystallogra-
phy [29]. Accessibility of the FIV Env binding site on the
ligand-engaged form of CD134 may facilitate the trans-
mission of FIV bound to the surface of dendritic cells
(through DC-SIGN [30]) to adjacent CD134-expressing
CD4+ T cells. However, as FIV infection is modulated by
engagement of CD134 by CD134L [15], a scenario may
also be envisaged in which the Env-CD134 interaction
modulates signalling through CD134. CD134-engage-
ment by CD134L recruits TNFR-associated factors
(TRAFs) to the cytoplasmic tail of the molecule and
triggers an NF-kB1-dependent signalling pathway; if
native Env acts as a CD134 agonist, viral attachment to
CD134 may promote the expansion and survival of the
very target cells required for FIV replication. Conversely,
if Env acts as an antagonist, attachment to CD134 may
contribute to the selective depletion of FIV-specific
CD4+ T cells.
CD134-usage and transmission
If CD134 CRD2-dependent infection is a signature of
FIV isolates from the ‘early’ stage of infection, such
‘early’ virus strains would appear to be the most appro-
priate targets for vaccine development. Assuming that
both CRD2-dependent and CRD2-independent viruses
are transmitted from an infected animal to a recipient
during biting, what happens to CRD2-independent
viruses following transmission? Are CRD2-independentwww.sciencedirect.com viruses filtered from the inoculum during the process of
transmission, analogous to the filtering of X4 variants of
HIV-1 as articulated in the ‘gatekeeper’ hypothesis
[31,32]? To resolve this question, a synthetic FIV qua-
sispecies was prepared comprising matched doses of six
clonal variants, identical in gag and pol but with unique
envs derived from either CRD2-dependent or indepen-
dent variants of FIV GL8. Following experimental trans-
mission of this reconstituted quasispecies to naive
animals, a selective expansion of CRD2-dependent
viruses was observed [33]. CRD2-independent viruses
failed to thrive in vivo, achieving lower proviral loads.
Further, the failure of the CRD2-independent viruses to
thrive was independent of early neutralising antibody or
cytotoxic T cell responses [33]. These data suggest that
CRD2-dependent viruses are able to replicate more effi-
ciently in the host. Thus, clear parallels exist between the
dominance of CCR5-dependent strains of HIV-1 and
CD134 CRD2-dependent strains of FIV during early
infection, culminating in the efficient targeting of a
specific CD4+ helper T cell population.
What drives the emergence of CD134 CRD2-
independent viruses?
The Fel-O-Vax FIV vaccine (Pfizer Inc.) combines inac-
tivated virus and inactivated cells with a proprietary
adjuvant. At the core of the vaccine is the FL4 strain
of FIV, a derivative of the prototypic (and CRD2-inde-
pendent) Petaluma isolate of FIV. The Env of FL4 is
curious in that it lacks two potential sites for N-linked
glycosylation that are highly conserved amongst the
majority of field strains of virus. The T271I and
N342Y mutations in FL4 lie in a loop region that is
similar in location to the V1V2 loop of HIV. When
identical mutations were incorporated into the Envs of
either GL8 or C-PGammer, receptor usage was switched
from CRD2-dependent to CRD2-independent [34].
Given the role of N-linked glycosylation in shielding
Env from the humoral immune response, the humoral
response to infection may offer a driving force for the
switch from CRD2-dependent to CRD2-independent
infection. Consistent with this hypothesis, viral variants
that emerged in vivo following infection with a clonal
preparation of GL8, and which resisted neutralisation by
homologous serum, displayed a shift in receptor usage
from CRD2-dependent to CRD-2 independent [23]. For
one variant, exchange of the hypervariable V5 loop of Env
alone was sufficient to render the virus both neutralising
antibody resistant and CRD2-independent [23]. As poly-
clonal sera elicited in infected cats can be remarkably
mono-specific, targeting single determinants in the vari-
able loops of the virus [35,36], in vivo escape from
neutralisation may be sufficient to drive the emergence
of CRD2-independent viruses. In doing so, the progeny
viruses may gain the ability to spread into additional
cellular compartments through a direct (CD134-indepen-
dent) interaction with CXCR4 [17].Current Opinion in Virology 2013, 3:670–675
674 Virus replication in animals and plantsConclusions
The replication of FIV in vivo may be influenced by both
host and viral factors; in this review we have focussed on
the Env–CD134 interaction. However, replication may
also be influenced by additional viral determinants; tran-
scriptional regulation by the long terminal repeats
(LTRs) and the accessory gene orfA [37–41] and the
ability of the virus to evade intrinsic immune factors such
as APOBEC proteins [38,42]. Given that the virus–re-
ceptor interaction is the initial event in retroviral replica-
tion, understanding the intricacies of the Env–CD134
relationship will inform future strategies for the devel-
opment of both FIV vaccines and therapeutics. Moreover,
as the lentiviruses of cats and humans have evolved two
distinct strategies to selectively target infection of CD4+
helper T cells, inter-species comparisons offer a unique
opportunity to discern what makes immunodeficiency-
causing lentiviruses tick.
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